- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06945718
Klinische resultaten van indocyanine groene tracer met behulp van laparoscopische gastrectomie met uitgebreide lymfadenectomie voorbij D2 voor lokaal geavanceerde maagkanker (Fuges-30)
Prospectieve gerandomiseerde gecontroleerde onderzoeken op klinische resultaten van indocyaninegroene tracer met behulp van laparoscopische gastrectomie met D2 extra-regionale lymfeklierdissectie voor lokaal geavanceerde maagkanker (Fuges-30) (Fuges-30)
Taking patients with locally advanced gastric adenocarcinoma (cT2-4a, N-/+, M0) as the research subjects, to evaluate whether the clinical efficacy of laparoscopic beyond D2 regional lymph node dissection for gastric cancer with indocyanine green tracer is better or not.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Mi Lin, phD
- Telefoonnummer: 13459152658
- E-mail: silihuala@qq.com
Studie Contact Back-up
- Naam: Hua-Long Zheng, phD
- Telefoonnummer: 18359190587
- E-mail: 291167038@qq.com
Studie Locaties
-
-
Fujian
-
Fuzhou, Fujian, China, 350001
- Werving
- Fujian Medical University Union Hospital
-
Contact:
- Changming Huang, M.D., Ph.D.
- Telefoonnummer: +86-133-6591-0253
- E-mail: hcmlr2002@163.com
-
Hoofdonderzoeker:
- Changming Huang, M.D., Ph.D.
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Age from 18 to 75 years Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy cT2-4a, N-/+, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual, 8th Edition
Beschrijving
Inclusion Criteria:
Age from 18 to 75 years Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy cT2-4a, N-/+, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual, 8th Edition No distant metastasis, no direct invasion of pancreas, spleen or other adjacent organs in the preoperative examinations Performance status of 0 or 1 on the ECOG (Eastern Cooperative Oncology Group) scale ASA (American Society of Anesthesiology) class I to III Written informed consent
Exclusion Criteria:
Women during pregnancy or breast-feeding Severe mental disorder History of previous upper abdominal surgery (except for laparoscopic cholecystectomy) History of previous gastric surgery (including ESD/EMR for gastric cancer) Enlarged or bulky regional lymph node (diameter over 3cm) supported by preoperative imaging including enlarged or bulky lymph nodes in D3 region.
Other malignant disease within the past 5 years History of unstable angina or myocardial infarction within past six months History of cerebrovascular accident within past six months History of continuous systematic administration of corticosteroids within one month Requirement for simultaneous surgery for other disease Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer FEV1 (forced expiratory volume in one second)<50% of predicted values Diffuse invasive gastric cancer Tumors preoperatively confirmed to involve the squamocolumnar junction or duodenum History of an iodine allergy Patients who declined laparoscopic surgery
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
laparoscopic gastrectomy with beyond D2 regional fluorescent lymph node dissection with ICG group
ICG with D2+ group |
dissect the lymph nodes outside the extent of D2 LN region. |
|
laparoscopic gastrectomy with D2 regional lymph node dissection with ICG group
ICG with D2 group |
dissect the lymph nodes outside the extent of D2 LN region. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
3-year disease free survival rate
Tijdsspanne: 3 years
|
Disease-free survival is calculated from the day of surgery to the day of recurrence or death |
3 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Total number of retrieved lymph nodes
Tijdsspanne: 30 days
|
Total number of retrieved lymph nodes |
30 days
|
|
Noncompliance rate of lymph node dissection
Tijdsspanne: 30 days
|
The LN dissection rate was determined by the number of patients in whom a LN station was harvested divided by the total number of patients who required retrieval at the corresponding LN station. Within the scope of D2 dissection, LN noncompliance was defined as the absence of LNs that should have been resected from > 1 LN station. |
30 days
|
|
Relationship between fluorescent lymph nodes in group A and total number of lymph nodes in group A
Tijdsspanne: 30 days
|
Relationship between the number of fluorescent lymph nodes in group A and total number of lymph nodes in group A |
30 days
|
|
Relationship between fluorescent lymph nodes in Group A and positive lymph nodes in Group A (positive rate)
Tijdsspanne: 30 days
|
The number of positive lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (True positive rate). |
30 days
|
|
Relationship between fluorescent lymph nodes in Group A and negative lymph nodes in Group A (false positive rate)
Tijdsspanne: 30 days
|
The number of negative lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (false positive rate). |
30 days
|
|
Relationship between non-fluorescent lymph nodes in Group A and negative lymph nodes in group A (negative rate)
Tijdsspanne: 30 days
|
The number of negative lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in group A (True negative rate). |
30 days
|
|
Relationship between nonfluorescent lymph nodes in Group A and positive lymph nodes in Group A (false negative rate)
Tijdsspanne: 30 days
|
The number of positive lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in Group A (false negative rate). |
30 days
|
|
Relationship between fluorescent lymph nodes in group B and total number of lymph nodes in group B
Tijdsspanne: 30 days
|
Relationship between the number of fluorescent lymph nodes in group B and total number of lymph nodes in group B |
30 days
|
|
Relationship between fluorescent lymph nodes in Group B and positive lymph nodes in Group B (positive rate)
Tijdsspanne: 30 days
|
The number of positive lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group B (True positive rate). |
30 days
|
|
Relationship between fluorescent lymph nodes in Group B and negative lymph nodes in Group B (false positive rate)
Tijdsspanne: 30 days
|
The number of negative lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (false positive rate). |
30 days
|
|
Relationship between non-fluorescent lymph nodes in Group B and negative lymph nodes in group B (negative rate)
Tijdsspanne: 30 days
|
The number of negative lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in group B (True negative rate). |
30 days
|
|
Relationship between nonfluorescent lymph nodes in Group B and positive lymph nodes in Group B (false negative rate)
Tijdsspanne: 30 days
|
The number of positive lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in Group B (false negative rate). |
30 days
|
|
Number of metastatic lymph nodes
Tijdsspanne: 30 days
|
Number of metastatic lymph nodes |
30 days
|
|
Metastasis rate of lymph nodes
Tijdsspanne: 30 days
|
Metastasis rate of lymph nodes |
30 days
|
|
Postoperative complications
Tijdsspanne: 30 days
|
Postoperative complications were evaluated within 30 days following surgery. These postoperative complications include gastrointestinal-related complications, incision-related complications, respiratory complications, cardiovascular and cerebrovascular complications, urinary system complications, infection complications, embolism complications, and other complications. The grading of postoperative complications adopts the Clavien-Dindo classification. |
30 days
|
|
Mortality rates
Tijdsspanne: 30 days
|
Patient died during hospitalization. |
30 days
|
|
3-year overall survival rate
Tijdsspanne: 3 years
|
3-year overall survival rate |
3 years
|
|
3-year recurrence pattern
Tijdsspanne: 3 years
|
3-year recurrence pattern |
3 years
|
|
Postoperative recovery course
Tijdsspanne: 30 days
|
Time to first flatus after surgery, time to first ambulation after surgery, time to first liquid diet after surgery, time to first semi-liquid diet after surgery, length of hospital stay after surgery. |
30 days
|
|
The incidence of intraoperative complications
Tijdsspanne: 30 days
|
Intraoperative complications were defined as bleeding due to named vessel injury, injury to visceral organs, mechanical factor-related problems, cardiopulmonary dysfunction due to hypercapnia, and other complications |
30 days
|
|
Inflammatory and immune response
Tijdsspanne: 7 days
|
the values of hemoglobin, prealbumin, albumin, C-reactive protein, and white blood cell count from peripheral blood before the operation and on postoperative day 1, 3, 5 are recorded. |
7 days
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Chang-Ming Huang, Prof., Fujian Medical University Union Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- FUGES-30
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .